Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 12.5% Higher – Here’s What Happened

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s stock price rose 12.5% during trading on Thursday . The company traded as high as $3.76 and last traded at $3.9050. Approximately 6,754,697 shares were traded during mid-day trading, a decline of 60% from the average daily volume of 16,972,451 shares. The stock had previously closed at $3.47.

Wall Street Analyst Weigh In

RXRX has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. dropped their target price on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a research report on Thursday, April 30th. Morgan Stanley increased their target price on shares of Recursion Pharmaceuticals from $5.00 to $5.50 and gave the company an “equal weight” rating in a research report on Thursday, May 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 21st. Bank of America dropped their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 25th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday, May 7th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $8.10.

Recursion Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.47 and a current ratio of 5.47. The company has a market capitalization of $2.04 billion, a PE ratio of -3.21 and a beta of 1.04. The company’s 50-day simple moving average is $3.29 and its 200-day simple moving average is $3.82.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.08. Recursion Pharmaceuticals had a negative net margin of 842.95% and a negative return on equity of 54.33%. The company had revenue of $6.47 million for the quarter, compared to the consensus estimate of $15.78 million. During the same period last year, the firm posted ($0.50) EPS. Recursion Pharmaceuticals’s revenue for the quarter was down 56.8% on a year-over-year basis. As a group, sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.02 earnings per share for the current year.

Insiders Place Their Bets

In other Recursion Pharmaceuticals news, CEO Najat Khan sold 28,298 shares of the firm’s stock in a transaction on Monday, March 9th. The shares were sold at an average price of $3.35, for a total transaction of $94,798.30. Following the transaction, the chief executive officer directly owned 2,262,085 shares of the company’s stock, valued at approximately $7,577,984.75. This trade represents a 1.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Blake Borgeson sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $3.52, for a total value of $105,600.00. Following the sale, the director owned 6,199,863 shares of the company’s stock, valued at $21,823,517.76. This trade represents a 0.48% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 96,254 shares of company stock valued at $320,369. Insiders own 8.43% of the company’s stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Large investors have recently modified their holdings of the stock. International Assets Investment Management LLC purchased a new stake in shares of Recursion Pharmaceuticals during the fourth quarter worth approximately $31,000. Allworth Financial LP boosted its holdings in shares of Recursion Pharmaceuticals by 85.6% in the third quarter. Allworth Financial LP now owns 9,548 shares of the company’s stock valued at $47,000 after acquiring an additional 4,403 shares in the last quarter. Sequoia Financial Advisors LLC purchased a new stake in shares of Recursion Pharmaceuticals in the fourth quarter valued at about $41,000. IFP Advisors Inc boosted its holdings in shares of Recursion Pharmaceuticals by 81.5% in the third quarter. IFP Advisors Inc now owns 10,355 shares of the company’s stock valued at $51,000 after acquiring an additional 4,650 shares in the last quarter. Finally, Savant Capital LLC purchased a new stake in shares of Recursion Pharmaceuticals in the third quarter valued at about $54,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.